Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Novo Nordisk's flagship diabetes and weight-loss drugs, Ozempic and Wegovy, have come under heightened scrutiny after the ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...

The UK's MHRA have issued a warning to people on birth control who may also be taking drugs like Ozempic, Wegovy or Mounjaro ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.

The European Medicines Agency said an eye condition that might cause loss of vision is a very rare side effect of Novo Nordisk's blockbuster drugs Ozempic and Wegovy.

Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide.

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...

The EMA’s drug safety committee launched a review of medicines containing semaglutide — the active ingredient in Ozempic, Wegovy and Rybelsus — in January.

The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare eye condition that can lead to ...

Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...